Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials

被引：0
|
作者：
Lebwohl, M. [1 ]
Ghislain, P-D [2 ]
Kerdel, F. [3 ]
Gu, Y. [4 ]
Valdes, J. [4 ]
Thompson, E. H. [5 ]
Lynde, C. [6 ]
机构：
[1] Mt Sinai Hlth Syst, New York, NY USA
[2] UCL St Luc, Brussels, Belgium
[3] Florida Acad Dermatol Ctr, Miami, FL USA
[4] AbbVie Inc, N Chicago, IL USA
[5] AbbVie Inc, Redwood City, CA USA
[6] Lynde Ctr Dermatol & Prob Med Res, Markham, ON, Canada
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2019年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P096
引用
收藏
页码：115 / 116
页数：2
相关论文
共 50 条
  • [1] Efficacy of Risankizumab compared with placebo across subgroups in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Lebwohl, M.
    Ghislain, P.
    Kerdel, F.
    Gu, Y.
    Valdes, J. M.
    Thompson, E. H.
    Lynde, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E25 - E25
  • [2] Impact of Prior Treatment History on Efficacy of Risankizumab Compared with Placebo in Patients with Moderate-to-Severe Plaque Psoriasis: Integrated Analyses from Three Phase 3 Trials
    Strober, B.
    Lambert, J.
    Gu, Y.
    Thompson, E. H.
    Valdecantos, W. C.
    Menter, A.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E24
  • [3] Impact of prior treatment history on efficacy of Risankizumab compared with placebo in patients with moderate-to-severe plaque psoriasis: integrated analyses from three phase 3 trials
    Strober, B.
    Lambert, J.
    Gu, Y.
    Zhan, T.
    Thompson, E. Z.
    Valdecantos, W. C.
    Menter, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 117 - 117
  • [4] Durable efficacy of risankizumab compared with ustekinumab across subgroups of patients with moderate-to-severe plaque psoriasis: Integrated analysis of two phase 3 trials
    Foley, Peter
    Strober, Bruce
    Valdecantos, Wendell C.
    Photowala, Huzefa
    Zhan, Tianyu
    Menter, Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB49 - AB49
  • [5] Efficacy and safety of Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis: Results from the Phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Kruger, J. G.
    Tsai, T.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2019, 28 (03) : E24 - E25
  • [6] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [7] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [8] Efficacy and safety of risankizumab (RZB) compared with adalimumab (ADA) in patients with moderate-to-severe plaque psoriasis: results from the phase 3 IMMvent trial
    Reich, K.
    Gooderham, M.
    Thaci, D.
    Crowley, J. J.
    Ryan, C.
    Krueger, J. G.
    Tsai, T. -F.
    Flack, M.
    Gu, Y.
    Williams, D. A.
    Thompson, E. H. Z.
    Paul, C.
    EXPERIMENTAL DERMATOLOGY, 2018, 27 : 9 - 10
  • [9] Exposure-response relationships for efficacy and safety of risankizumab in patients with moderate to severe plaque psoriasis: Integrated analyses of phase 2 and 3 clinical trials
    Khatri, Amit
    Suleiman, Ahmed A.
    Polepally, Akshanth R.
    Othman, Ahmed A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB209 - AB209
  • [10] Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials
    Menter, M. Alan
    Papp, Kim A.
    Cather, Jennifer
    Leonardi, Craig
    Pariser, David M.
    Krueger, James G.
    Wohlrab, Johannes
    Amaya-Guerra, Mario
    Kaszuba, Andrzej
    Nadashkevich, Oleg
    Tsai, Tsen-Fang
    Gupta, Pankaj
    Tan, Huaming
    Valdez, Hernan
    Mallbris, Lotus
    Tatulych, Svitlana
    JOURNAL OF DRUGS IN DERMATOLOGY, 2016, 15 (05) : 568 - 580
12345